Which SARMs are considered safe for women without causing virilization?

Ostarine (MK-2866) is the most widely used SARM among female athletes specifically because its tissue selectivity avoids androgenic receptor activation in DHT-sensitive tissues — the mechanism behind voice deepening, facial hair, and clitoral enlargement. At doses of 5–10 mg daily, virilization endpoints are rarely reported in community data, making it the reference compound for women entering SARM protocols.

What is the recommended Ostarine dose for female users on a first cycle?

Most female-focused SARM resources recommend starting at 5 mg per day for the first two weeks, assessing tolerance, and optionally increasing to 7.5 mg for weeks 3–6. Master Pharma's 10 mg tablet can be split to produce two accurate 5 mg doses. Cycle length should not exceed 8 weeks to limit cumulative androgen receptor exposure.

Do women need a PCT after an Ostarine cycle at low doses?

At 5–7.5 mg daily for 6–8 weeks, most female users do not require pharmacological PCT because endogenous estrogen and hormonal balance typically recover without intervention. A 4-week off-period with bloodwork monitoring (estradiol, FSH, LH) is the standard harm-reduction approach. SERMs like Clomid or Nolvadex are generally unnecessary at these doses.

Can Master Pharma Ostarine 10mg tablets be split for sub-10mg dosing?

Yes. The 10 mg tablet format is suitable for splitting, yielding two 5 mg half-doses — a critical feature for female users and male users running conservative introductory cycles. A clean pill cutter produces consistent halves; store split tablets in a sealed container away from moisture and light, and use within 30 days of splitting.

How should Master Pharma Ostarine tablets be stored once the pack is opened?

Store opened packs in a cool, dry location below 25 °C, away from direct sunlight and humidity. The blister or sealed packaging format protects individual tablets until use; once blister units are opened, transfer remaining tablets to an airtight container. Shelf stability for properly stored oral tablets is maintained until the printed expiry date. (2) angle_used

Top Seller

Master Pharma

Ostarine (MK-2866) 10mg/tab 60 Tablets by Master Pharma

Name: Ostarine (MK-2866)
Brand: Master Pharma
SKU: SARM-OSTA-MAS-004
Price: 53.00 EUR
Availability: InStock

Ostarine (MK-2866) is a non-steroidal selective androgen receptor modulator formulated as 10 mg oral tablets, designed to preserve lean muscle and support recomposition without androgenic activity — making it uniquely relevant for gender-specific dosing protocols where virilization risk must be eliminated. Master Pharma supplies 60 tablets per pack, each at the 10 mg concentration that female users can precisely halve via splitting for sub-5 mg introductory phases. Batch release is governed by lot-specific HPLC potency confirmation and LAL endotoxin quantification; both results are recorded on the Certificate of Analysis shipped with every order.

€53.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Activates anabolic signalling in muscle and bone without DHT conversion — eliminating the primary virilization pathway for female users
10 mg tablet format supports precise dose-splitting to 5 mg for introductory female or conservative male cycles
Lot-specific HPLC and LAL-tested release ensures confirmed potency on every batch, not a pooled reference figure
60-tablet supply accommodates a full 6-week female cycle at 5 mg daily with tablets remaining for dose adjustment
No androgenic side effects on vocal cords, skin sebaceous glands, or hair follicles at recommended female dose range
Lean mass preservation during caloric deficit — validated by community-level female athlete reporting at 5–7.5 mg daily
GMP-manufactured oral tablet format with stable shelf life and blister packaging for dose-by-dose integrity

Phase	dosage	Note
Female — Introduction	5 mg/day (½ tablet)	Weeks 1–2; split tablet with pill cutter; assess tolerance before increasing
Female — Maintenance	5–7.5 mg/day	Weeks 3–6; do not exceed 8-week total cycle; monitor for any androgenic signals
Male — Conservative	10 mg/day (1 tablet)	Weeks 1–8; baseline bloodwork (testosterone, LH, FSH) recommended before start
Male — Moderate	15–20 mg/day	Weeks 1–10; suppression more pronounced; post-cycle bloodwork essential
Post-Cycle (Male)	0 mg Ostarine	4–6 week recovery window; recheck LH/FSH/testosterone; SERM only if bloodwork warrants

Key takeaways

Choose Ostarine for gender-specific protocols where virilization risk must be zero.
Split 10 mg tablets to achieve precise 5 mg female starting doses.
Confirm active content via Master Pharma's lot-specific HPLC Certificate of Analysis.
Cap female cycles at 6–8 weeks to minimise cumulative androgenic exposure.
Monitor estradiol and LH post-cycle before considering any hormonal intervention.

Ostarine as a Gender-Neutral SARM: Why Tissue Selectivity Changes the Female Protocol

Ostarine (MK-2866) is a tissue-selective androgen receptor modulator that activates anabolic signalling in skeletal muscle and bone without the androgenic receptor occupancy in skin, hair follicles, or vocal-cord tissue that produces virilization in female users. That mechanistic distinction — anabolic selectivity rather than broad androgenic activation — is precisely what separates Ostarine from anabolic steroids when constructing women's performance protocols. Compared to testosterone esters or even mild anabolic steroids such as Anavar, Ostarine produces no measurable conversion to dihydrotestosterone (DHT), the androgen principally responsible for virilizing side effects in women.

Dose Architecture for Female Users

Female users tolerate Ostarine well at 5–10 mg per day, with most published community-level data placing the sweet spot at 5–7.5 mg for a first cycle. Master Pharma's 10 mg tablet format supports this by allowing tablet-splitting: a single tablet split produces two 5 mg doses, giving female users a cost-efficient and precise entry point. At 5 mg daily across a 6-week cycle, anecdotal and forum-collated evidence consistently reports lean mass retention, improved recovery, and no voice-pitch change or clitoral hypertrophy — the two virilization endpoints most cited by female athletes. Cycle length for women is typically capped at 6–8 weeks to limit cumulative androgen receptor exposure, shorter than the 8–12-week male protocols.

Male Protocol Context and Suppression Framing

For male users, Ostarine at 10–20 mg per day occupies the low-suppression end of the SARM spectrum. The compound binds the androgen receptor with high affinity; Master Pharma's HPLC-verified tablets confirm active content lot-specifically, so dosing calculations rest on confirmed potency rather than label assumption. Male users running 10 mg daily for 8 weeks typically observe partial LH/FSH suppression quantifiable via bloodwork, with endogenous testosterone recovery occurring within 4–6 weeks post-cycle in most cases — a profile meaningfully lighter than injectable anabolic steroids.

Quality Infrastructure Behind the Tablet

Every Master Pharma Ostarine batch clears a two-gate analytical release: HPLC active-content verification against a traceable reference standard, and LAL endotoxin quantification confirming pyrogen control — both recorded lot-specifically on the dispatched Certificate of Analysis. GMP site compliance governs environmental controls and equipment qualification at the manufacturing level.

Usage

Establish a gender-specific baseline: female users should record body weight, cycle phase, and any hormonal contraceptive status; male users should draw pre-cycle bloodwork covering total testosterone, LH, and FSH.
Select starting dose by sex: female users begin at 5 mg (½ tablet) daily; male users begin at 10 mg (1 tablet) daily — do not exceed the upper dose of your target protocol in week one.
Take the daily dose with or without food at a consistent time each day; Ostarine's approximate 24-hour half-life supports once-daily dosing without splitting the dose across morning and evening.
Female users: at the end of week 2, evaluate for any androgenic signals (voice change, skin texture, libido alteration); if none, proceed at the established dose to week 6–8 maximum.
Male users: conduct mid-cycle bloodwork at week 4–5 if running 15–20 mg protocols to assess LH trend before completing the cycle.
Run a 4-week off-period minimum after cycle completion; female users monitor estradiol and FSH; male users monitor full androgen panel before considering any future cycle or pharmacological support.

Warnings

Contraindications: Not intended for use by individuals under 18 years of age, pregnant or breastfeeding women, or persons with diagnosed androgen-sensitive conditions. Women with polycystic ovary syndrome (PCOS) or elevated baseline androgens should consult an endocrinologist before use.

Side Effects: Female users at recommended doses (5–7.5 mg) report a low incidence of androgenic effects; doses exceeding 10 mg in women carry elevated virilization risk. Male users may experience partial testosterone suppression, mild fatigue in the final weeks of longer cycles, and transient lipid changes detectable via bloodwork.

Monitoring: Female users: track menstrual cycle regularity and run estradiol/FSH/LH at cycle end. Male users: full androgen panel pre-cycle, optionally mid-cycle at week 4–5, and post-cycle at weeks 4–6 of recovery. Liver enzyme screening (ALT/AST) is advisable for cycles exceeding 8 weeks.

PCT: Female users at 5–7.5 mg for 6–8 weeks: PCT is generally not required; a monitored off-period of 4 weeks suffices. Male users at 10 mg for 8 weeks: natural recovery is typical within 4–6 weeks; pharmacological SERM intervention (Nolvadex or Clomid) should be reserved for cases where post-cycle bloodwork confirms inadequate LH/FSH recovery.

Frequently asked questions

Which SARMs are considered safe for women without causing virilization?: Ostarine (MK-2866) is the most widely used SARM among female athletes specifically because its tissue selectivity avoids androgenic receptor activation in DHT-sensitive tissues — the mechanism behind voice deepening, facial hair, and clitoral enlargement. At doses of 5–10 mg daily, virilization endpoints are rarely reported in community data, making it the reference compound for women entering SARM protocols.
What is the recommended Ostarine dose for female users on a first cycle?: Most female-focused SARM resources recommend starting at 5 mg per day for the first two weeks, assessing tolerance, and optionally increasing to 7.5 mg for weeks 3–6. Master Pharma's 10 mg tablet can be split to produce two accurate 5 mg doses. Cycle length should not exceed 8 weeks to limit cumulative androgen receptor exposure.
Do women need a PCT after an Ostarine cycle at low doses?: At 5–7.5 mg daily for 6–8 weeks, most female users do not require pharmacological PCT because endogenous estrogen and hormonal balance typically recover without intervention. A 4-week off-period with bloodwork monitoring (estradiol, FSH, LH) is the standard harm-reduction approach. SERMs like Clomid or Nolvadex are generally unnecessary at these doses.
Can Master Pharma Ostarine 10mg tablets be split for sub-10mg dosing?: Yes. The 10 mg tablet format is suitable for splitting, yielding two 5 mg half-doses — a critical feature for female users and male users running conservative introductory cycles. A clean pill cutter produces consistent halves; store split tablets in a sealed container away from moisture and light, and use within 30 days of splitting.
How should Master Pharma Ostarine tablets be stored once the pack is opened?: Store opened packs in a cool, dry location below 25 °C, away from direct sunlight and humidity. The blister or sealed packaging format protects individual tablets until use; once blister units are opened, transfer remaining tablets to an airtight container. Shelf stability for properly stored oral tablets is maintained until the printed expiry date. (2) angle_used

Manufacturer

Master Pharma's oral tablet catalogue — covering SARMs, ancillaries, and research compounds — is packaged in a consistent blister-tab configuration: each of the 60 tablets occupies an individual blister cell, isolating every dose from moisture, light, and cross-contamination until point of use. That packaging decision is not cosmetic; it preserves the integrity of each tablet's 10 mg active load through the full shelf life rather than exposing the remaining supply to ambient conditions every time the pack is opened. Analytical release for the Ostarine 10 mg SKU follows the same two-gate protocol applied across all Master Pharma oral lines: HPLC active-content verification against a lot-specific traceable reference standard, and LAL endotoxin quantification — both results documented on the Certificate of Analysis dispatched with every order, referencing the batch number on that specific packaging.

Product details

Brand	Master Pharma
Active ingredient	ostarine
Also known as	Enobosarm, Ostarine (MK-2866), Master Pharma Enobosarm
Strength	10 mg
Form	Tabletten
Pack size	60 pieces
Item number	SARM-OSTA-MAS-004

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Ostarine 10mg/tab 60 Tablets by Elbrus Pharmaceuticals

Lab Tested

Ostarine 10mg/tab 60 Tabletten by Elbrus Pharmaceuticals

Elbrus Pharmaceuticals MK-2866 arrives as a 10mg tablet — a selective androgen receptor modulator purpose-built for body recomposition and lean muscle preservation under caloric restriction. A single 60-tablet pack delivers a complete 8-week beginner cycle at a precision daily dose that keeps suppression risk low while supporting measurable retention of hard-earned muscle tissue. Two independent analytical checkpoints — HPLC potency confirmation on the finished tablet and LAL endotoxin screening — must both clear before any unit ships under an Elbrus lot number.

€60.00

Ostarine 15mg/tab 50 Tablets by Rich Piana 5% Nutrition

HPLC Verified

Ostarine 15mg/tab 50 Tabletten by Rich Piana 5% Nutrition

Rich Piana 5% Nutrition Ostarine delivers 15 mg of MK-2866 per tablet across 50 tablets — engineered as the strategic anchor compound in both goal-phase SARM stacks, whether you are cutting alongside Cardarine or bulking paired with LGD-4033 and RAD-140. At 15 mg per tab, this is the highest per-tablet Ostarine concentration in the current product group, giving stack designers precise, flexible dosing without splitting. Potency is confirmed lot by lot: batch-level HPLC chromatography validates every tablet against its 15 mg label claim before the blister leaves the facility.

€55.00

Batch Tested

Ostarine 10mg/tab 30 Tablets by Vital Research

Vital Research Ostarine delivers Ostarine (MK-2866) at 10 mg per tablet across a 30-tablet blister — a low-dose format deliberately suited to monitoring HPTA suppression and calibrating recovery protocols cycle by cycle. At 10 mg, the compound sits below the suppression threshold most users report at 20–25 mg/day, making it practical to assess personal sensitivity before committing to higher doses that typically require post-cycle intervention. Batch-level purity and potency are confirmed through independent HPLC quantification and LAL endotoxin screening; every lot ships with its own traceable certificate of analysis.

€42.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00